Next Article in Journal
Canadian Melanoma Conference Recommendations on High-Risk Melanoma Surveillance: A Report from the 14th Annual Canadian Melanoma Conference; Banff, Alberta; 20–22 February 2020
Previous Article in Journal
Results from a Theory-Guided Survey to Support Breast Cancer Trial Participation: Barriers, Enablers, and What to Do about them
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 28
Issue 3
10.3390/curroncol28030188
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study

by
Camille Tessier
1,
Thomas Allard
1,
Jean-Samuel Boudreault
2,†,
Rayan Kaedbey
3,†,
Vincent Éthier
1,
Fléchère Fortin
1 and
Michel Pavic
1,4,*,†
1
Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC J1H 5H3, Canada
2
Hôpital Universitaire du Sacré-Cœur de Montréal, Montreal, QC H4J 1C5, Canada
3
Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada
4
Centre de Recherche du CHUS (CRCHUS), Sherbrooke, QC J1H 5N4, Canada
*
Author to whom correspondence should be addressed.
†
Membres of Groupe des Maladies Plasmocytaires du Québec.
Curr. Oncol. 2021, 28(3), 2029-2039; https://doi.org/10.3390/curroncol28030188
Submission received: 25 March 2021 / Revised: 20 April 2021 / Accepted: 21 May 2021 / Published: 26 May 2021
(This article belongs to the Section Hematology)
Browse Figure
Versions Notes

Abstract

Background—smoldering multiple myeloma (SMM) risk of progression to multiple myeloma (MM) is highly heterogeneous and several models have been suggested to predict this risk. Lakshman et al. recently proposed a model based on three biomarkers: bone marrow plasma cell (BMPC) percentage > 20%, free light chain ratio (FLCr) > 20 and serum M protein > 20 g/L. The goal of our study was to test this “20/20/20” model in our population and to determine if similar results could be obtained in another cohort of SMM patients. Method—we conducted a retrospective, single center study with 89 patients diagnosed with SMM between January 2008 and December 2019. Results—all three tested biomarkers were associated with an increased risk of progression: BMPC percentage ≥ 20% (hazard ratio [HR]: 4.28 [95%C.I., 1.90–9.61]; p < 0.001), serum M protein ≥ 20 g/L (HR: 4.20 [95%C.I., 1.90–15.53]; p = 0.032) and FLCr ≥ 20 (HR: 3.25 [95%C.I., 1.09–9.71]; p = 0.035). The estimated median time to progression (TTP) was not reached for the low and intermediate risk groups and was 29.1 months (95%C.I., 3.9–54.4) in the high-risk group (p = 0.006). Conclusions—the 20/20/20 risk stratification model adequately predicted progression in our population and is easy to use in various clinical settings.
Keywords: smoldering multiple myeloma; multiple myeloma; risk stratification model smoldering multiple myeloma; multiple myeloma; risk stratification model

Share and Cite

MDPI and ACS Style

Tessier, C.; Allard, T.; Boudreault, J.-S.; Kaedbey, R.; Éthier, V.; Fortin, F.; Pavic, M. Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study. Curr. Oncol. 2021, 28, 2029-2039. https://doi.org/10.3390/curroncol28030188

AMA Style

Tessier C, Allard T, Boudreault J-S, Kaedbey R, Éthier V, Fortin F, Pavic M. Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study. Current Oncology. 2021; 28(3):2029-2039. https://doi.org/10.3390/curroncol28030188

Chicago/Turabian Style

Tessier, Camille, Thomas Allard, Jean-Samuel Boudreault, Rayan Kaedbey, Vincent Éthier, Fléchère Fortin, and Michel Pavic. 2021. "Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study" Current Oncology 28, no. 3: 2029-2039. https://doi.org/10.3390/curroncol28030188

APA Style

Tessier, C., Allard, T., Boudreault, J.-S., Kaedbey, R., Éthier, V., Fortin, F., & Pavic, M. (2021). Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study. Current Oncology, 28(3), 2029-2039. https://doi.org/10.3390/curroncol28030188

Article Metrics

Back to TopTop